Ohtuvayre (Ensifentrine)-Ensifentrine specifications and dosage forms

Ohtuvayre (Ensifentrine) - Ensifentrine is an inhaled drug used for the treatment of chronic obstructive pulmonary disease (COPD). Its special dosage form and specifications make it of great significance in clinical application. Ensifentine is a sterile aqueous inhalation suspension that appears yellow to light yellow. Its active ingredient Ensifentrine has a significant inhibitory effect on phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). This dual mechanism helps improve lung function and relieve respiratory symptoms.

Ohtuvayre is supplied as a 2.5 ml sterile suspension containing 1.2 mg of exefantine per ml. Specifically, each unit dose ampoule contains 3 mg of exefantine dissolved in an aqueous solution at pH 6.7. The formula of the aqueous solution includes disodium hydrogen phosphate, sodium dihydrogen phosphate, polysorbate 20, sodium chloride, sorbitan monolaurate and water for injection, ensuring the stability and biocompatibility of the drug. This design not only improves the solubility of the drug, but also promotes its uniform dispersion during aerosol inhalation.

Before using Ohtuvayre for nebulization treatment, the patient is required to shake the ampoule vigorously to ensure that the active ingredients are completely resuspended. Since the effect of aerosol inhalation is affected by many factors, including individual differences in patients, the atomization system used, and the performance of the air compressor, in clinical application, doctors need to choose appropriate equipment based on the specific conditions of the patient. Of note, Ohtuvayre can only be administered through a standard jet nebulizer connected to an air compressor. This requirement ensures that the drug can be effectively delivered to the lungs to exert its therapeutic effect. .

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6433c98-41a0-4f99-8f7f-d0e9db6e3f40